Tag Archives: Healthcare

Panel Announcement: Big Data in Healthcare

20 Oct

By Christine A. Wu, Senior Research Analyst, LSN


LSN is pleased to publish its first panel announcement for RESI SF 2017: Big Data in Healthcare. On January 10th, a panel of five expert healthcare investors will speak regarding why they’re looking for big data investment opportunities, how they identify technologies that will have an impact on the healthcare system landscape, and what early-stage fundraising companies in this exciting new vertical can do to get a foot in their doors.

The Big Data in Healthcare panel will comprise of the following panelists:

The big data space has increasingly become exciting with its potential to transform healthcare through its cross-correlation of a number of broad applications – computer vision, machine learning, patient medical records, disease diagnoses, mental health trends and proposed therapies, as well as many other spaces in healthcare. If you haven’t yet, be sure to register now for this tremendous educational opportunity in this booming space, while also having the chance to meet valuable investors in-person.



RESI does Toronto, where health means business. Lots of it.

14 Apr

By Dianne Carmichael, Managing Director, Health Innovation & Venture Services, MaRS Discovery District


The Redefining Early Stage Investments (RESI) Conference is going abroad for the first time. RESI on MaRS will take place on June 23rd in Toronto, the heart of Canada’s financial and health industries, where early stage investment in life sciences and digital health is on the cusp of a major breakthrough.

Take the launch of Johnson & Johnson’s JLABS @ Toronto in May — also a first outside the United States, and in the very same building RESI will take place, the 1.5-million-square-foot building that is MaRS Discovery District. Or the recently announced centre for advanced therapeutic cell technologies, the first of its kind in the world, which is also moving into MaRS thanks to a $40-million collaboration between the government of Canada, GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM).

These initiatives offer a glimpse of how major strategic firms and investors in the health sector are recognizing the Toronto area’s resources, including the region’s pool of skilled talent, its recognized high quality of life, its world-class health research institutions, its strong entrepreneurial culture, and the generous tax incentives available for R&D locally.

While local early stage investing in life sciences picked up last year, venture capital players are still few and far between in Canada. Total venture deal activity for Canada’s life sciences sector hit $511 million (all values in Canadian dollars) for the first nine months of 2015 — a jump from $422.5 million the year before. Canadian companies closing major deals during 2015 included Highland Therapeutics ($50 million) and Trillium Therapeutics ($55.2 million). Another three Canadian life sciences companies collectively cut deals worth $114 million in 2015 — Clementia Pharmaceuticals ($60 million), Northern Biologics (US$30 million) and Profound Medical ($24 million).

Early stage investors active in the Canadian health sector are also tapping into medical devices and the digital health sector, which includes consumer apps that help people manage their own health. Toronto, already known as the City of Apps, is particularly poised to take advantage of the crossover between health and digital technologies that is fuelling innovation in wearables. Precision medicine and robotics are some of the other areas gaining traction in the Canadian investment scene.

The intersection between 3D printing and health is also taking off with Autodesk Toronto and their award-winning research division moving to MaRS, the fastest growing technology and medical research community in Canada. There are over 100 researchers at Autodesk global, 60 of them based in Toronto. This team is already breaking new ground using 3D-printing technology to develop low-cost, prosthetic limb sockets and build highly realistic human models for biomechanical simulation and research. Future developments include 3D bioprinting: the production of living cells from simple tissues to complete organs. The market for this is expected to reach $2.84 billion globally by 2022 and Canada is poised to be a leading player.

Canada is also home to a diverse variety of early stage investment sources. In addition to VC firms such as Lumira Capital, Genesys Capital, Versant Ventures Canada and CTI Life Sciences, Canada also has many other types of active investors. The local angel investment community is becoming more active in the health sector, and many institutional investors already have a strong presence. That is the case of the heavyweight Caisse de Dépôt et Placement du Québec, which manages public and private pension funds.

Canada is also experiencing a rise in capital for health startups from the social impact and venture philanthropy investment trend, which Canada is pioneering. Virgin Unite, Richard Branson’s foundation that links innovators and entrepreneurial ideas to challenge tough issues and improve peoples’ lives, has just recently partnered with the MaRS Centre for Impact Investing to launch the MaRS Catalyst Fund. One third of this early-stage, cross-Canada direct investment fund will be put toward the health sector.

As interest ramps up on the early stage investmenet front, MaRS is growing its support for entrepreneurs, including expanding its team of advisors with experience in early stage investment. This includes a health entrepreneur advisory board chaired by Stefan Larsen, CEO of Northern Biologics, to support accelerating companies that can scale globally.

The graph is trending upwards in Toronto’s early stage health investment sector. RESI on MaRS will welcome innovators and investors from around the globe to engage in the heart of Canada’s rising health innovation hub in Toronto.


RESI Panel Announcement: Healthcare System Partners

31 Mar

By Shaoyu Chang, MD, MPH, Senior Research Manager, LSN

Shaoyu 10*10

The RESI team is pleased to debut a new panel on Healthcare System Partners at RESI@TMCx on April 11. In an article titled “Innovation as Discipline, Not Fad,” the New England Journal of Medicine called on healthcare organizations to embrace innovations and serve as the training ground to test their medical benefits, technical feasibility, and business viability. Many healthcare systems are doing just that. This panel will reveal the changing role healthcare organizations are playing in fostering innovation.

Moderated by Rebecca Kaul, Chief Innovation Officer, MD Anderson, this session will feature:

From innovation centers to investment vehicles, healthcare organizations have become critical partners for entrepreneurs. Whether you are considering generating user experience, conducting pilot studies, or receiving technical guidance, the value of face-to-face meetings with these institutions is unfathomable. At the heart of the world’s largest medical center, this panel will help entrepreneurs navigate complex healthcare systems and bring their companies to the next milestone.

Registering for the RESI Conference will give you the opportunity to listen to this panel live, connect with relevant investors and network with like-minded entrepreneurs.


Hot Life Science Investor Mandate 2: Health Insurance Provider Seeking Shipping Medical Devices/Diagnostics

10 Jul

A US based Health Insurance Provider makes investments in healthcare companies from an evergreen investment fund.  Allocation sizes are highly varied, but are most often $3-5 million.  While the firm is open to opportunities globally, the organization only invests in companies that are targeting the US healthcare market (including companies with products that have been commercialized in other markets and are seeking capital to expand into the US market).

The firm invests in transformative medical technologies that will lower the cost of care provision, and has previously made investments in healthcare IT and in wearable sensors for elderly patients.  The firm only invests in companies that have attained regulatory approval for their products, or which do not require approval.  The fund does not invest in therapeutics, but is open to investing in diagnostic technologies that will lower the cost of care.  In the medical device sector, the firm is generally not interested in invasive devices such as implantable.

While the firm is open to investing in any indication area, the firm’s focus is on population health and the firm is therefore primarily interested in indications with a large number of patients, including cancer, diseases of the nervous system, and diabetes.

The firm invests in both pre-revenue companies and companies with existing revenues, but does not invest in companies that still face regulatory barriers to attaining revenue.  The firm has long-term horizons for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 1: Singapore VC Fund Looking to Help Companies Expand to Asia

3 Jul

A venture capital firm based in Singapore is looking to make early, growth, expansion, and mezzanine stage investments in the healthcare sector. The firm typically invests in the Series A and B rounds. The firm has raised two funds to date. The firm seeks to invest in non-Asian companies that are interested in entering the Asian market; investment funds are prioritized to companies looking to set up operations in Singapore. The firm will also invest in companies based in Asia. The investment size is variable depending on the stage of the company; ranging from $1M to $10M or more. The firm will consider opportunities from around the globe and is actively seeking new investment opportunities. 

The firm seeks to invest in biopharmaceuticals, diagnostics, and medical devices. For therapeutics, the firm prefers novel small molecules and biologics targeting indications in large markets. The firm prefers to invest in platform technologies and typically invests in clinical stage opportunities. For medical devices, the firm prefers devices in the later stages of development or near commercialization. The firm seeks a strong management team and considers both private and public companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 1: VC Arm of Larger Fund Looks to Grow in 2013 – January 22, 2013

22 Jan

A fund located in North America with around $200 million in current AUM will grow to $400 million in assets by the end of 2013. The fund is the venture capital arm of a larger fund with AUM upward of $50 billion. Over the last 12 months, the group has allocated to more than 10 firms, making the VC number one in its region. The firm is currently looking for new opportunities in the life science space within the next 6-9 months. They typically allocate anywhere between $500,000 and $50 million per firm. The group is a lifecycle investor, which allows them to deploy capital throughout a firm’s entire financing lifecycle, and thus participate in every round of financing.

The firm is currently looking for companies in the information provider space, and is particularly interested in healthcare IT firms. The firm has a global investment mandate, but prefers North American targets for allocation.

The firm almost entirely invests in companies that are pre-revenue, but will consider companies that are not cash-flow-positive. The fund will consider firms with products on the market on a discretionary basis, but has no strict requirements in terms of their EBITDA or annual revenue.

Hot Life Science Investor Mandate 2: Large Family Office Looking for Opportunities in Medtech Subsectors – January 22, 2013

22 Jan

A family office located in the Western US with around $100 million in assets is looking for a compelling opportunity for allocation within the next 6-9 months. The office invested in more than five deals in 2012, typically between $1-5 million per firm.

The foundation is most interested in medical devices, and will look at firms within the full gamut of medtech subsectors. Typically, the office allocates to firms that have at least one product on the market. They have no strict criteria in terms of a firm’s EBITDA or revenue, but require that any firm in which they invest has goals to lower the cost of healthcare.

%d bloggers like this: